Saturday, February 03, 2018 2:19:44 AM
Recent Support of Countermeasure Development Poised to Continue in Reauthorization of PAHPA
January 29, 2018
"Targeted threats included influenza, Ebola, Zika, Marburg, anthrax, plague, glanders, tularemia, and Middle East Respiratory Syndrome Coronavirus or “MERS-CoV.”
"..the upcoming reauthorization of the Pandemic and All-Hazards Preparedness Act (“PAHPA”), and its prior reauthorization, may present a critical opportunity to continue to improve public-private relationships in countermeasure development.
"Since the passage of the 21st Century Cures Act, various components of the U.S. Government have continued to support countermeasure development.
"As detailed in a recent report, the U.S. Government made a wide range of investments for countermeasures and diagnostic throughout 2017 in the form of funding, expertise, and other resources.
"Targeted threats included influenza, Ebola, Zika, Marburg, anthrax, plague, glanders, tularemia, and Middle East Respiratory Syndrome Coronavirus or “MERS-CoV.”
" the program incentivizes development by providing vouchers to sponsors of new approved countermeasures that target specific threats.
"The vouchers can be used to expedite the FDA’s review of other products, which in turn can result in early market entry and effectively extend the productive life of associated patent rights.
"September 30 deadline for reauthorizing PAHPA." 8 months away
https://www.insidegovernmentcontracts.com/2018/01/recent-support-of-countermeasure-development-poised-to-continue-in-reauthorization-of-pahpa/
Recent AEMD News
- Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture Devices • PR Newswire (US) • 02/21/2024 01:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 10:15:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:15:41 PM
- Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update • PR Newswire (US) • 02/14/2024 09:15:00 PM
- Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 14, 2024 • PR Newswire (US) • 02/07/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 11:06:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 11:04:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 11:02:52 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 12/22/2023 09:01:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 12:49:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2023 09:15:39 PM
- Aethlon Medical Announces Fiscal Second Quarter Financial Results and Provides Corporate Update • PR Newswire (US) • 11/14/2023 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 01:01:36 PM
- Aethlon Medical Announces Appointment of James B. Frakes, M.B.A. as Interim Chief Executive Officer and Guy Cipriani, M.B.A. as Chief Operating Officer • PR Newswire (US) • 11/13/2023 01:01:00 PM
- Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 14, 2023 • PR Newswire (US) • 11/06/2023 01:01:00 PM
- Aethlon Receives Clearance From Drug Controller General of India For Potential Phase 1 Trial of its Hemopurifier® in Oncology • PR Newswire (US) • 10/10/2023 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2023 09:05:12 PM
- Aethlon Announces Reverse Stock Split • PR Newswire (US) • 10/04/2023 12:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/29/2023 09:57:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/29/2023 09:56:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/29/2023 09:54:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2023 01:00:08 PM
- Aethlon Medical to Present at the H.C. Wainwright 25th Annual Global Investment Conference • PR Newswire (US) • 08/30/2023 12:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 09:15:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 08:20:32 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM